Skip to main content
. 2016 Jan 13;7(6):7280–7296. doi: 10.18632/oncotarget.6906

Figure 1. Expression of CXCR2 and its ligands progressively increases in the developing cancerous lesions of Pdx1-cre;LSL-Kras(G12D) mouse model.

Figure 1

A. Representative photomicrograph of immunohistochemistry performed on progression model derived from tumors of Pdx1-cre;LSL-Kras(G12D) mice at different ages (n = 5 mice per group), demonstrating progressively increasing expression of mCXCL1, mCXCL3, mCXCL5 and mCXCR2. The normal pancreas is negative. B. Expression of transcripts of Cxcr2 and its ligands Cxcl1, 2, 3, 5 and 7 in the KRAS-PDAC cells. C. Immunofluorescence for detection of mCXCR2 on KRAS-PDAC cells. D. Expression of mCXCL2, 5 and 7 in culture supernatants of KRAS-PDAC cells, as measured by ELISA.